US EditionNovo Nordisk's obesity drug falls short against Eli Lilly's in trial
CagriSema showed 20.2% weight loss at 84 weeks versus tirzepatide's 23.6%, causing a 13% share drop and a new 52-week low for Novo Nordisk, data showed.
- On Monday, Novo Nordisk A/S shares plunged and hit a 52-week low after REDEFINE 4 failed to meet the primary non-inferiority endpoint for weight loss versus tirzepatide at 84 weeks.
- The 84-week REDEFINE 4 trial showed 809 subjects compared once-weekly CagriSema 2.4/2.4 mg with tirzepatide 15 mg, reporting weight loss of 20.2% vs 23.6% and 23% vs 25.5% favoring tirzepatide.
- CagriSema showed a generally safe profile, with most gastrointestinal adverse events mild to moderate and diminishing over time, while investors expressed concern over its uphill launch, Markus Manns, Union Investment said.
- Novo Nordisk says it will keep testing higher doses and combinations, expects FDA decision late 2026, and faces a setback as shares fell nearly 50% last year.
- Novo Nordisk plans a higher-dose CagriSema trial initiation in the second half of 2026 and expects the REDEFINE 11 readout in the first half of 2027, Martin Holst Lange said.
18 Articles
18 Articles
Novo Nordisk's New Obesity Drug Fails a Big Test
Novo Nordisk just learned its latest much-hyped obesity drug may not actually live up to the hype. Shares of the Danish pharma giant plunged 16% Monday after it reported that its experimental drug, CagriSema, did not match the weight loss achieved by Eli Lilly's rival drug in a direct comparison...
Cagrisema shows lower weight loss than Eli Lilly's active ingredient tirzepatide in a new study. Novo shares fall.
The pharmaceutical company hopes for billions of sales with the weight loss syringe Cagrisma. In a comparative study with the rival Eli Lilly, the active ingredient is disappointed. Shareholders react soberly.
Novo’s Next-Generation Obesity Shot Falls Short of Lilly Rival
Novo Nordisk A/S’s next-generation obesity shot CagriSema delivered less weight loss than Eli Lilly & Co.’s rival blockbuster in a trial, another blow to the experimental drug’s sales potential that could limit its role in the weight-loss market.
Coverage Details
Bias Distribution
- 60% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
